Market Research Logo

PharmaPoint: Seasonal Influenza Vaccines - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Seasonal Influenza Vaccines - Global Drug Forecast and Market Analysis to 2025

Summary

Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses, designated as influenza Type A, B, and C. The infection’s rapid onset and potential for high morbidity and mortality, particularly in high-risk patient populations such as the elderly and young children, make prompt and effective treatment with antiviral medication very difficult. For these reasons, prophylactic vaccination is the preferred intervention for seasonal influenza.

Today, available vaccines include the older egg-based, adjuvanted and non- adjuvanted inactivated vaccines, along with live-attenuated vaccines and newer, cell culture-based seasonal influenza vaccines. Within these four vaccine classes, continuous improvements in the formulation of vaccines has occurred over the years, with the market currently transitioning from trivalent to quadrivalent formulations, which offer protection against an additional B strain of the virus. The anticipated launch of quadrivalent, cell culture-based VLP vaccines will have the potential to revolutionize the approaches used to protect against seasonal influenza infections. GlobalData expects the global seasonal influenza vaccines market - which, for the purposes of this report, comprises the seven major pharmaceutical markets (7MM; US, France, Germany, Italy, Spain, UK, Japan) - to grow moderately during the next decade at a CAGR of 3.3%, reaching total sales of $4.3 billion by 2025.

Highlights

Key Questions Answered

  • Based on interviews with key opinion leaders (KOLs), GlobalData has identified key unmet needs in the seasonal influenza vaccine marketplace.
  • What will be the effect of recent and upcoming changes in national immunization schedules?
  • How will the upcoming first-in-class Virus-Like Particle (VLP) vaccine be received in the different markets?
  • What research and development (R&D) strategies will companies leverage to compete in the future seasonal influenza vaccine marketplace?
  • Which patient population(s) are most likely to be targeted by seasonal influenza vaccines?
Key Findings
  • GlobalData has calculated that the global seasonal influenza vaccine market generated about $3.1 billion in sales in 2015. This global market is expected to grow modestly at a Compound Annual Growth Rate (CAGR) of 3.3%, reaching sales of $4.3 billion by 2025. The majority of this growth will occur in the 5EU, driven by the uptake of egg-based, quadrivalent vaccines. Further growth is anticipated due to the launch of cell-culture. quadrivalent vaccines in the 7MM. The seasonal influenza vaccines market in the 5EU is expected to grow at a CAGR of 5.5%, reaching sales of $1 billion by 2025. GlobalData estimates sales in the US to grow moderately at a CAGR of 3.5% during the next 10 years, reaching $2.6 billion by 2025, while Japan will experience marginal growth, with a CAGR of 0.3%.
  • KOLs interviewed by GlobalData repeatedly identified the effectiveness of seasonal influenza vaccines as the number one unmet need. They argued that the influenza virus rapid antigenic drift coupled to a time-consuming egg-based vaccine manufacturing approach are barriers to increasing vaccine efficacy and duration.
  • GlobalData anticipates that opportunities will center on the improvement of vaccine long-term efficacy whilst addressing the cost effectiveness concerns voiced by various governmental institutions.
Scope
  • Overview of seasonal influenza, including epidemiology, etiology, pathophysiology, as well current routine seasonal influenza vaccine recommendations of all 7MM covered.
  • Top-line seasonal influenza vaccine market revenue from 2015-2025. Recent acquisitions, approvals and governmental recommendations are included in the forecast model.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the seasonal influenza vaccine market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.
  • Analysis of the current and future market competition in the global seasonal influenza vaccine marketplace. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global seasonal influenza vaccine market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the seasonal influenza vaccine market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Symptoms and Prognosis
4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global Trends
4.3.1 Historical Perspective of Vaccination Coverage
4.3.2 Laboratory Confirmed Influenza Cases
4.3.3 Hospitalization Due to Influenza
4.3.4 Influenza Averted Cases
4.4 Forecast Methodology
4.4.1 Sources Used Tables
4.4.2 Forecast Assumptions and Methods
4.4.3 Sources Not Used
4.5 Epidemiological Forecast for Seasonal Influenza (2015-2025)
4.5.1 Seasonal Influenza Vaccination
4.5.2 Seasonal Influenza Vaccination Rates
4.5.3 Diagnosed Outpatient Influenza-Like Illness Incident Cases
4.5.4 Lab Confirmed Incident Cases of Seasonal Influenza
4.5.5 Influenza-Related Hospitalized Incident Cases
4.5.6 Cases Averted by Seasonal Influenza Vaccinations
4.6 Discussion
4.6.1 Epidemiological Forecast Insight
4.6.2 Limitations of Analysis
4.6.3 Strengths of Analysis
5 Disease Management
5.1 Seasonal Influenza Immunization Policy
5.1.1 Immunization Recommendations and Most Frequently Administered Seasonal Influenza Vaccines
5.2 US
5.2.1 Influenza Immunization Recommendations and Policies
5.2.2 Clinical Practice
5.3 France
5.3.1 Influenza Immunization Recommendations and Policies
5.3.2 Clinical Practice
5.4 Germany
5.4.1 Influenza Immunization Recommendations and Policies
5.4.2 Clinical Practice
5.5 Italy
5.5.1 Influenza Immunization Recommendations and Policies
5.5.2 Clinical Practice
5.6 Spain
5.6.1 Influenza Immunization Recommendations and Policies
5.6.2 Clinical Practice
5.7 UK
5.7.1 Influenza Immunization Recommendations and Policies
5.7.2 Clinical Practice
5.8 Japan
5.8.1 Influenza Immunization Recommendations and Policies
5.8.2 Clinical Practice
6 Competitive Assessment
6.1 Overview
6.2 Product Profiles - Major Brands, Inactivated Vaccines
6.2.1 Fluzone Quadrivalent
6.2.2 Fluzone High-Dose
6.2.3 Fluzone Intradermal
6.2.4 Vaxigrip
6.2.5 Fluarix Tetra
6.2.6 Fluvirin
6.2.7 Afluria
6.2.8 Agrippal
6.3 Product Profiles - Major Brands, Inactivated Vaccines (Adjuvanted)
6.3.1 Fluad
6.4 Product Profiles - Major Brands, Live-Attenuated Vaccines
6.4.1 FluMist Quadrivalent
6.5 Product Profiles - Major Brands, Cell Cultured Vaccines
6.5.1 Flublok
6.5.2 Flucelvax
6.6 Other Seasonal Influenza Vaccines
6.6.1 Influvac
6.6.2 Minor Brands
7 Unmet Needs and Opportunity Analysis
7.1 Overview
7.2 Higher Level of Public Awareness and Positive Perception of Influenza Vaccines
7.2.1 Unmet Need
7.2.2 Gap Analysis
7.2.3 Opportunity
7.3 Immunization Policies Targeting Children and Adolescents
7.3.1 Unmet Need
7.3.2 Gap Analysis
7.3.3 Opportunity
7.4 Enhanced Vaccine Efficacy in High-Risk Groups
7.4.1 Unmet Need
7.4.2 Gap Analysis
7.4.3 Opportunity
7.5 Vaccines Leveraging Innovative and Efficient Manufacturing Technologies
7.5.1 Unmet Need
7.5.2 Gap Analysis
7.5.3 Opportunity
7.6 Improving the Cost-Effectiveness of Influenza Vaccines
7.6.1 Unmet Need
7.6.2 Gap Analysis
7.6.3 Opportunity
7.7 Vaccines with Broader Influenza Strain Coverage
7.7.1 Unmet Need
7.7.2 Gap Analysis
7.7.3 Opportunity
7.8 Improved Vaccine Safety Profile
7.8.1 Unmet Need
7.8.2 Gap Analysis
7.8.3 Opportunity
8 Pipeline Assessment
8.1 Overview
8.2 Promising Vaccines in Clinical Development
8.2.1 Seasonal Influenza VLP Vaccine
8.2.2 VN-100
8.2.3 Quadrivalent Seasonal Influenza VLP Vaccine
8.3 Promising Vaccines in Early-Stage Development
8.3.1 FLU-v
8.3.2 M-001
8.3.3 TAK-850
8.3.4 VAX-2012Q
8.4 Other Vaccines in Development Outside the 7MM
9 Current and Future Players
9.1 Overview
9.2 Trends in Corporate Strategy
9.3 Company Profiles - Major Players
9.3.1 Sanofi
9.3.2 CSL Limited (Seqirus)
9.3.3 GlaxoSmithKline
9.3.4 AstraZeneca (MedImmune)
9.3.5 Protein Sciences Corporation
9.3.6 Mitsubishi Tanabe Pharma
9.3.7 Novavax
9.4 Other Companies
9.4.1 Mylan
9.4.2 Daiichi Sankyo
10 Market Outlook
10.1 Global Markets
10.1.1 Forecast
10.1.2 Drivers and Barriers - Global Issues
10.2 US
10.2.1 Forecast
10.2.2 Key Events
10.2.3 Drivers and Barriers
10.3 France
10.3.1 Forecast
10.3.2 Key Events
10.3.3 Drivers and Barriers
10.4 Germany
10.4.1 Forecast
10.4.2 Key Events
10.4.3 Drivers and Barriers
10.5 Italy
10.5.1 Forecast
10.5.2 Key Events
10.5.3 Drivers and Barriers
10.6 Spain
10.6.1 Forecast
10.6.2 Key Events
10.6.3 Drivers and Barriers
10.7 United Kingdom
10.7.1 Forecast
10.7.2 Key Events
10.7.3 Drivers and Barriers
10.8 Japan
10.8.1 Forecast
10.8.2 Key Events
10.8.3 Drivers and Barriers
11 Appendix
11.1 Bibliography
11.2 Abbreviations
11.3 Methodology
11.4 Forecasting Methodology
11.4.1 Vaccine Coverage
11.4.2 Vaccines Included
11.4.3 Key Launch Dates
11.4.4 Influenza Vaccine Tender System Assumptions
11.4.5 General Pricing Assumptions
11.4.6 Individual Vaccine Assumptions
11.4.7 Pricing of Pipeline Agents
11.5 Primary Research - KOLs Interviewed for this Report
11.6 Primary Research - Prescriber Survey
11.7 About the Authors
11.7.1 Analyst
11.7.2 Therapy Area Director
11.7.3 Epidemiologists
11.7.4 Director of Epidemiology
11.7.5 Global Director of Therapy Analysis and Epidemiology
11.8 About GlobalData
11.9 Disclaimer
1.1 List of Tables
Table 1: Notable Influenza Pandemics
Table 2: Influenza Symptoms
Table 3: Risk Factors and Comorbidities for Seasonal Influenza
Table 4: 7MM, Historical Perspective of Seasonal Influenza Vaccination Coverage
Table 5: 7MM, Sources of Epidemiological Data Used to Forecast Total Population Vaccination Rates of Seasonal Influenza
Table 6: 7MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incident Cases of Outpatient Seasonal ILI
Table 7: 7MM, Sources of Epidemiological Data Used to Forecast Laboratory Confirmed Incident Cases of Seasonal Influenza
Table 8: 7MM, Sources of Epidemiological Data Used to Forecast Seasonal Influenza-Related Hospitalized Incident Cases
Table 9: 7MM, Sources of Epidemiological Data Used to Forecast Averted Cases of Seasonal Influenza
Table 10: 7MM, Sources Not Used in Epidemiological Analysis of Seasonal Influenza
Table 11: 7MM, People Receiving Seasonal Influenza Vaccination, All Ages, Both Sexes, N, Selected Years 2015-2025
Table 12: 7MM, Age-Specific Distribution of People Receiving Seasonal Influenza Vaccination, Both Sexes, N (Row %), 2015
Table 13: 7MM, Sex-Specific Distribution of People Receiving Seasonal Influenza Vaccination, All Ages, N (Row %), 2015
Table 14: 7MM, Seasonal Influenza Vaccination Rates, All Ages, Both Sexes, %, Selected Years 2015-2025
Table 15: 7MM, Age-Specific Seasonal Influenza Vaccination Rates, Both Sexes, (%), 2015
Table 16: 7MM, Diagnosed Outpatient ILI Incident Cases, All Ages, Both Sexes, N, Selected Years 2015-2025
Table 17: 7MM, Age-Specific Diagnosed Outpatient ILI Incident Cases, Both Sexes, N (Row %), 2015
Table 18: 7MM, Sex-Specific Diagnosed Outpatient ILI Incident Cases, All Ages, N (Row %), 2015
Table 19: 7MM, Lab Confirmed Incident Cases of Seasonal Influenza, All Ages, Both Sexes, N, Selected Years 2015-2025
Table 20: 7MM, Age-Specific Lab Confirmed Incident Cases of Seasonal Influenza, Both Sexes, N (Row %), 2015
Table 21: 7MM, Lab Confirmed Incident Cases of Seasonal Influenza, All Ages, N (Row %), 2015
Table 22: 7MM, Influenza-Related Hospitalized Incident Cases, All Ages, Both Sexes, N, Selected Years 2015-2025
Table 23: 7MM, Age-Specific Influenza-Related Hospitalized Incident Cases, Both Sexes, N (Row %), 2015
Table 24: 7MM, Influenza Related Hospitalized Incident Cases, All Ages, N (Row %), 2015
Table 25: 7MM, Cases Averted by Seasonal Influenza Vaccinations, All Ages, Both Sexes, N, Selected Years 2015-2025
Table 26: 7MM, Age-Specific Cases Averted by Seasonal Influenza Vaccinations, Both Sexes, N (Row %), 2015
Table 27: Seasonal Influenza Immunization Recommendation Agencies by Country, 2016
Table 28: Immunization Recommendations and Most Frequently Administered Seasonal Influenza Vaccines, 2016
Table 29: Country Profile - US
Table 30: Country Profile - France
Table 31: Country Profile - Germany
Table 32: Country Profile - Italy
Table 33: Country Profile - Spain
Table 34: Country Profile - UK
Table 35: Country Profile -Japan
Table 36: Leading Seasonal Influenza Vaccines, 2016
Table 37: Product Profile - Fluzone Quadrivalent
Table 38: Immunogenicity Profile of Fluzone Quadrivalent
Table 39: Local and Systemic AEs of Fluzone Quadrivalent
Table 40: Fluzone Quadrivalent SWOT Analysis, 2016
Table 41: Global Sales Forecast ($m) for Fluzone Quadrivalent, 2015-2025
Table 42: Product Profile - Fluzone High-Dose
Table 43: Immunogenicity of Fluzone High-Dose Compared with Fluzone
Table 44: Local and Systemic AEs of Fluzone High-Dose
Table 45: Fluzone High-Dose SWOT Analysis, 2016
Table 46: Global Sales Forecast ($m) for Fluzone High-Dose, 2015-2025
Table 47: Product Profile - Fluzone Intradermal
Table 48: Comparison of Fluzone Intradermal Quadrivalent Versus Fluzone Intradermal Trivalent
Table 49: Local andsystemic AEs of Fluzone Intradermal Quadrivalent
Table 50: Fluzone Intradermal Quadrivalent SWOT Analysis, 2016
Table 51: Global Sales Forecast ($m) for Fluzone/Intanza Intradermal, 2015-2025
Table 52: Product Profile - Vaxigrip
Table 53: Cumulative Incidence of Influenza Infection in Children
Table 54: Local and Systemic AEs of Vaxigrip
Table 55: Vaxigrip SWOT Analysis, 2016
Table 56: Global Sales Forecast ($m) for Vaxigrip, 2015-2025
Table 57: Product Profile - Fluarix Tetra
Table 58: Immunogenicity Profile of Fluarix Tetra
Table 59: Local and Systemic AEs of Fluarix Tetra
Table 60: Fluarix Tetra SWOT Analysis, 2016
Table 61: Global Sales Forecast ($m) for Fluarix Tetra, 2015-2025
Table 62: Product Profile - Fluvirin
Table 63: Immunogenicity of Fluvirin in Adults
Table 64: Local and Systemic AEs of Fluvirin
Table 65: Fluvirin SWOT Analysis, 2016
Table 66: Global Sales Forecast ($m) for Fluvirin, 2015-2025
Table 67: Product Profile - Afluria
Table 68: Immunogenicity of Afluria in Adults
Table 69: Local and Systemic AEs of Afluria
Table 70: Afluria SWOT Analysis, 2016
Table 71: Global Sales Forecast ($m) for Afluria, 2015-2025
Table 72: Product Profile - Agrippal
Table 73: Immunogenicity of Agrippal
Table 74: Local and Systemic AEs of Agrippal
Table 75: Agrippal SWOT Analysis, 2016
Table 76: Global Sales Forecast ($m) for Agrippal, 2015-2025
Table 77: Product Profile - Fluad
Table 78: Immunogenicity Comparison of Fluad Versus Agriflu
Table 79: Local and Systemic AEs of Fluad
Table 80: Fluad SWOT Analysis, 2016
Table 81: Global Sales Forecast ($m) for Fluad, 2015-2025
Table 82: Product Profile - FluMist Quadrivalent
Table 83: Noninferiority of FluMist Quadrivalent Compared with FluMist Trivalent
Table 84: AEs of FluMist Quadrivalent
Table 85: FluMist Quadrivalent SWOT Analysis, 2016
Table 86: Global Sales Forecast ($m) for FluMist Quadrivalent, 2015-2025
Table 87: Product Profile - Flublok
Table 88: Immunogenicity of Flublok compared with Fluzone and Fluzone High-Dose
Table 89: Local and Systemic AEs of Flublok
Table 90: Flublok SWOT Analysis, 2016
Table 91: Global Sales Forecast ($m) for Flublok, 2015-2025
Table 92: Product Profile - Flucelvax
Table 93: Immunogenicity of Flucelvax
Table 94: Local and Systemic AEs of Flucelvax
Table 95:Flucelvax SWOT Analysis, 2016
Table 96: Global Sales Forecast ($m) for Flucelvax, 2015-2025
Table 97: Summary of Other Marketed Seasonal Influenza Vaccines, 2016
Table 98: Unmet Need and Opportunity in Seasonal Influenza Vaccines, 2016
Table 99: Seasonal Influenza Vaccines - Late-Stage Pipeline, 2016
Table 100: Quadrivalent Versions of Marketed Vaccines
Table 101: Product Profile - Seasonal Influenza VLP Vaccine
Table 102: Seasonal Influenza VLP Vaccine SWOT Analysis, 2016
Table 103: Global Sales Forecast ($m) for Seasonal Influenza VLP Vaccine, 2015-2025
Table 104: Product Profile - VN-100
Table 105: Comparison of Immunogenicity Profile of VN-100 and Subcutaneous Standard Vaccine
Table 106: Frequency of Local and Systemic AEs of VN-100 Compared with a Comparator Subcutaneous Vaccine
Table 107: VN-100 SWOT Analysis, 2016
Table 108: Global Sales Forecast ($m) for VN-100, 2015-2025
Table 109: Product Profile - Quadrivalent Seasonal Influenza VLP Vaccine
Table 110: Quadrivalent Seasonal Influenza VLP Vaccine SWOT Analysis, 2016
Table 111: Global Sales Forecast ($m) for Quadrivalent Seasonal Influenza VLP Vaccine, 2015-2025
Table 112: Promising Vaccines in Early-Stage Development, 2016
Table 113: Summary of Seasonal Influenza Vaccines in Development Outside the 7MM, 2016
Table 114: Key Companies in the Seasonal Influenza Vaccines Market, 2016
Table 115: Sanofi’s Seasonal Influenza Vaccine Portfolio Assessment, 2016
Table 116: CSL Limited’s Seasonal Influenza Vaccine Portfolio Assessment, 2016
Table 117: GSK’s Seasonal Influenza Vaccine Portfolio Assessment, 2016
Table 118: AstraZeneca’s Seasonal Influenza Vaccine Portfolio Assessment, 2016
Table 119: Protein Sciences Corporation’s Seasonal Influenza Vaccine Portfolio Assessment, 2016
Table 120: Mitsubishi’s Seasonal Influenza Vaccine Portfolio Assessment, 2016
Table 121: Novavax’s Seasonal Influenza Vaccine Portfolio Assessment, 2016
Table 122: Global (7MM) Sales Forecasts ($m) for Seasonal Influenza Vaccines, 2015-2025
Table 123: Seasonal Influenza Vaccines Market - Drivers and Barriers, 7MM, 2015-2025
Table 124: Sales Forecasts ($m) for Seasonal Influenza Vaccines in the US, 2015-2025
Table 125: Key Events Impacting Sales for Seasonal Influenza in the US, 2015‒2025
Table 126: US Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025
Table 127: Sales Forecasts ($m) for Seasonal Influenza Vaccines in France, 2015 -2025
Table 128: Key Events Impacting Sales for Seasonal Influenza in France, 2015‒2025
Table 129: France Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025
Table 130: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Germany, 2015 -2025
Table 131: Key Events Impacting Sales for Seasonal Influenza in Germany, 2015‒2025
Table 132: Germany Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025
Table 133: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Italy, 2015-2025
Table 134: Key Events Impacting Sales for Seasonal Influenza in Italy, 2015‒2025
Table 135: Italy Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025
Table 136: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Spain, 2015 -2025
Table 137: Key Events Impacting Sales for Seasonal Influenza in Spain, 2015‒2025
Table 138: Spain Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025
Table 139: Sales Forecasts ($m) for Seasonal Influenza Vaccines in the UK, 2015-2025
Table 140: Key Events Impacting Sales for Seasonal Influenza in the UK, 2015‒2025
Table 141: UK Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025
Table 142: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Japan, 2015-2025
Table 143: Key Events Impacting Sales for Seasonal Influenza in Japan 2015‒2025
Table 144: Japan Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025
Table 145: Key Launch Dates
Table 146: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
1.2 List of Figures
Figure 1: Influenza Virus Structure
Figure 2: 7MM, Cases with Seasonal Influenza Vaccination, All Ages, Both Sexes, N, 2015-2025
Figure 3: 7MM, Age-Specific Cases with Seasonal Influenza Vaccination, Both Sexes, N, 2015
Figure 4: 7MM, Sex-Specific Distribution of People Receiving Seasonal Influenza Vaccination, All Ages, N, 2015
Figure 5: 7MM, Seasonal Influenza Vaccination Rates, All Ages, Both Sexes, %, 2015-2025
Figure 6: 7MM, Age-Specific Seasonal Influenza Vaccination Rates, Both Sexes, (%), 2015
Figure 7: 7MM, Diagnosed Outpatient ILI Incident Cases, All Ages, Both Sexes, N, Selected Years 2015-2025
Figure 8: 7MM, Age-Specific Diagnosed Outpatient ILI Incident Cases, Both Sexes, N, 2015
Figure 9: 7MM, Sex-Specific Diagnosed Outpatient ILI Incident Cases, All Ages, N, 2015
Figure 10: 7MM, Age-Standardized Diagnosed Outpatient ILI Incidence, All Ages, Cases per 100,000 Population, 2015
Figure 11: 7MM, Lab Confirmed Incident Cases of Seasonal Influenza, All Ages, Both Sexes, N, Selected Years 2015-2025
Figure 12: 7MM, Age-Specific Lab Confirmed Incident Cases of Seasonal Influenza, Both Sexes, N, 2015
Figure 13: 7MM, Lab Confirmed Incident Cases of Seasonal Influenza, All Ages, N, 2015
Figure 14: 7MM, Influenza-Related Hospitalized Incident Cases, All Ages, Both Sexes, N, Selected Years 2015-2025
Figure 15: 7MM, Age-Specific Influenza-Related Hospitalized Incident Cases, Both Sexes, N, 2015
Figure 16: 7MM, Influenza-Related Hospitalized Incident Cases, All Ages, N, 2015
Figure 17: 7MM, Cases Averted by Seasonal Influenza Vaccinations, All Ages, Both Sexes, N, Selected Years 2015-2025
Figure 18: 7MM, Age-Specific Cases Averted by Seasonal Influenza Vaccinations, Both Sexes, N, 2015
Figure 19: Seasonal Influenza Vaccines - Phase II/Phase III Pipeline, 2016
Figure 20: Competitive Assessment of the Late-Stage Pipeline Vaccines for Seasonal Influenza, 2015-2025
Figure 21: Company Portfolio Gap Analysis in Seasonal Influenza Vaccines, 2015-2025
Figure 22: Global (7MM) Sales for Seasonal Influenza Vaccines by Country, 2015 and 2025
Figure 23: Sales of Seasonal Influenza Vaccines by Class in the US, 2015 and 2025
Figure 24: Sales of Seasonal Influenza Vaccines by Class in France, 2015 and 2025
Figure 25: Sales of Seasonal Influenza Vaccines by Class in Germany, 2015 and 2025
Figure 26: Sales of Seasonal Influenza Vaccines by Class in Italy, 2015 and 2025
Figure 27: Sales of Seasonal Influenza Vaccines by Class in Spain, 2015 and 2025
Figure 28: Sales of Seasonal Influenza Vaccines by Class in the UK, 2015 and 2025
Figure 29: Sales of Seasonal Influenza Vaccines by Class in Japan, 2015 and 2025

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report